Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Tenax Therapeutics Inc | TENX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.35 | 0.00 | 0.00 | 0.00 | 1.35 | 20:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 1.31 | 1.39 | 0.08 | 5.76% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.00 | USD |
Tenax Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 9.10M | 6.74M | $ -6.81M | -9.04 | - | 5.12M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Tenax Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TENX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.33 | 1.45 | 1.31 | 1.3635 | 42k | 0.02 | 1.50% |
| 1 Month | 1.19 | 1.54 | 1.14 | 1.2603 | 123k | 0.16 | 13.45% |
| 3 Months | 1.3 | 1.68 | 1.1 | 1.3108 | 85k | 0.05 | 3.85% |
| 6 Months | 2.15 | 2.7 | 1.1 | 1.9048 | 315k | -0.8 | -37.21% |
| 1 Year | 5.16 | 6.39 | 1.03 | 1.6583 | 504k | -3.81 | -73.84% |
| 3 Years | 49 | 53 | 1.03 | 10.0517 | 472k | -47.65 | -97.24% |
| 5 Years | 81 | 95.2 | 1.03 | 14.6536 | 307k | -79.65 | -98.33% |
Tenax Therapeutics Description
| Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market. The company develops novel product candidates such as Levodimendan IV that have the potential to address various critical care conditions with a high unmet medical need. Its drugs help in the reduction of morbidity and mortality in cardiac surgery patients. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. |
